As of 20 November 2025, Dr Reddys Laboratories shares traded at ₹1,249.05, marking a modest day change of 0.44% from the previous close of ₹1,243.55. The stock’s intraday range spanned from ₹1,237.50 to ₹1,252.25, positioning it below its 52-week high of ₹1,404.60 but comfortably above the 52-week low of ₹1,025.90. This price action suggests a consolidation phase following prior volatility.
Examining the technical indicators, the Moving Average Convergence Divergence (MACD) presents a bearish signal on the weekly chart, while the monthly chart indicates a mildly bearish tone. This divergence between timeframes points to short-term selling pressure tempered by a less pronounced longer-term downtrend. The Relative Strength Index (RSI) remains neutral on both weekly and monthly scales, signalling an absence of overbought or oversold conditions and suggesting that momentum is currently balanced.
Bollinger Bands further illustrate this mixed momentum. On a weekly basis, the bands reflect a mildly bearish posture, indicating that price volatility has been skewed towards the lower band, often a sign of downward pressure. Conversely, the monthly Bollinger Bands show a sideways pattern, implying that the stock price is consolidating within a defined range without clear directional bias.
The daily moving averages provide a mildly bullish signal, hinting at some short-term upward momentum. This is complemented by the Dow Theory analysis, which shows a mildly bullish trend on the weekly chart but no definitive trend on the monthly timeframe. The KST (Know Sure Thing) indicator aligns with the MACD, showing bearish tendencies weekly and mildly bearish monthly, reinforcing the cautious tone in momentum.
On-Balance Volume (OBV) analysis reveals no clear trend on the weekly chart, while the monthly OBV is mildly bearish. This suggests that trading volumes have not decisively supported price movements recently, which may contribute to the sideways price action observed.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
From a returns perspective, Dr Reddys Laboratories has delivered mixed results relative to the broader Sensex index. Over the past week, the stock recorded a return of 1.61%, nearly double the Sensex’s 0.85% gain, indicating short-term outperformance. However, over the last month, the stock showed a decline of 0.55%, contrasting with the Sensex’s 1.47% rise, reflecting some recent weakness.
Year-to-date, Dr Reddys Laboratories’ stock price has declined by 10.03%, while the Sensex has advanced by 9.02%, highlighting a divergence in performance. Over the one-year horizon, the stock posted a 2.93% return, trailing the Sensex’s 9.81%. Longer-term returns tell a different story: over three years, the stock appreciated by 41.55%, slightly ahead of the Sensex’s 38.15%. Over five years, the stock’s 32.67% gain lagged the Sensex’s 95.38%, and over ten years, the stock’s 90.01% return was well below the Sensex’s 229.64%.
These figures illustrate that while Dr Reddys Laboratories has shown resilience and some periods of outperformance, it has generally lagged behind the broader market over extended periods. This performance context is important for investors analysing the stock’s technical momentum alongside fundamental market trends.
Is Dr Reddys Laboratories your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
In summary, the recent shift in Dr Reddys Laboratories’ technical parameters reflects a market in flux. The transition from a mildly bearish to a sideways trend suggests that investors are awaiting clearer directional cues. The mixed signals from MACD, RSI, moving averages, and volume-based indicators underscore the complexity of the current momentum landscape.
For market participants, this environment calls for careful monitoring of technical developments and price action. The stock’s proximity to its 52-week high and low, combined with the neutral RSI and mixed moving average signals, indicates that a breakout or breakdown could be imminent but is not yet confirmed.
Investors should also consider the broader pharmaceutical sector dynamics and macroeconomic factors that may influence Dr Reddys Laboratories’ performance. Given the stock’s varied returns relative to the Sensex, a comprehensive approach that integrates technical analysis with fundamental insights will be essential for informed decision-making.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
